GW043 emerges as a promising new compound in the treatment of depression showcasing rapid and significant antidepressant effects by targeting NMDA receptors (NMDARs). This mechanism offers hope for those suffering from depression and sheds light on the intricate mechanisms of synaptic plasticity and neurogenesis that underpin GW043’s therapeutic benefits. Highlights: GW043’s Mechanism of Action: GW043 …
A new antidepressant chemically named “GLYX-13” was developed by the biotech company Naurex for individuals with treatment-resistant depression. It is currently in clinical trials as an antidepressant augmentation strategy, meaning it is used as an add-on to already approved treatments. However, most evidence would suggest that it works extremely well as a standalone treatment option. …
Suboxone (Buprenorphine) is a medication that is used by people withdrawing from narcotics (opioids). It helps alleviate withdrawal symptoms and most people end up able to experience a smooth withdrawal while on this particular drug. In people that have either extreme or treatment-resistant depression, many have turned to trying a variety of drugs besides that …